Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won't come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
This eBook offers an overview of drug patents that were and are set to expire and highlights efforts by the FDA to stimulate the market for generics.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
According to a report, drugmakers are expected to lose $17 billion in worldwide sales due to patent expirations this year. Two reports list 18 drugs as losing patent protection or exclusivity, though not all drugs listed here will necessarily face generic or biosimilar competition in 2020.
Pinpointing the expiration date of drug patents can make filing taxes look like child's play. Each drug has wide ranging intellectual property, with timelines that are ever-changing. That said, here’s a list of 26 drugs that will probably go off patent in 2018.
From good news to bad news, 2017 was chock-full of noteworthy stories. But a few stood out among the rest. These are the five most-read articles published in 2017.
Gilead’s cure for Hepatitis C presents a prime example of the complicated nature of the drug pricing debate, and how patent rights can help determine pricing.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Drug patents are always more complicated than they seem, but a new infographic from Dickson Data spells out some of what you need to know in 2017, in an easily consumable way.
What drug patents are set to expire in 2017? It's hard to know. With so many 'evergreening' patent strategies and the added complexity of biologics and biosimilars, the proverbial patent cliff is becoming a thing of the past.